SCHEMBL20255462

SCHEMBL20255462

O=C(Cc1csc(-c2ccc(OC(F)(F)F)cc2)n1)N[C@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHMT2 P34897 1/20 0.55
▸ ACE P12821 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ PTBP1 P26599 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ P2RY14 Q15391 1/20 0.51
▸ MMP2 P08253 1/20 0.50
▸ MMP9 P14780 1/20 0.50
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ ITGB2 P05107 3/20 0.47
▸ ICAM1 P05362 3/20 0.47
▸ ITGAL P20701 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ERAP2 Q6P179 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ SHMT1 P34896 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20255808 1.00 SHMT2 (0.55) SHMT2ACEHTTLMNAMAPT
SCHEMBL20255990 0.91 P2RY14 (0.55) ACEHTTP2RY14KMT2AMEN1
SCHEMBL21560123 0.91 P2RY14 (0.55) ACEHTTP2RY14KMT2AMEN1
SCHEMBL20255602 0.89 KMT2A (0.61) ACEHTTP2RY14MMP2MMP9
SCHEMBL20255511 0.89 SHMT1 (0.56) ACEHTTLMNAMAPTSMN1; SMN2
SCHEMBL21560256 0.89 SHMT1 (0.56) ACEHTTLMNAMAPTSMN1; SMN2
SCHEMBL21560379 0.88 P2RY14 (0.58) ACEHTTLMNAMAPTSMN1; SMN2
SCHEMBL20255508 0.88 SHMT1 (0.57) ACEHTTLMNAMAPTP2RY14
SCHEMBL20255789 0.88 P2RY14 (0.61) ACEHTTMAPTSMN1; SMN2P2RY14
SCHEMBL20255603 0.86 POLB (0.63) ACEHTTP2RY14KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 — — US disclosed
WO-2018106636-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2018-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091451-B2 SHMT inhibitors and uses thereof SHMT1, SHMT2, BHMT SHMT2 2/4885ACE 2172/4885HTT 370/4885
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT SHMT2 2/4885ACE 2172/4885HTT 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback